Biotech entity
Gilead Sciences is most often covered alongside ViiV Healthcare, which appears in 2 of these 3 stories. pharma accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. They are less corroborated than the beat average, carrying 2 original sources each against 3.5 for the same window.
Last mentioned: 5d ago
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Gilead Sciences is most often covered alongside ViiV Healthcare, which appears in 2 of these 3 stories. pharma accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. They are less corroborated than the beat average, carrying 2 original sources each against 3.5 for the same window. That works out to roughly 0.1 stories per week across a 203-day span. Their average consequence score of 6.7 runs above the beat's 6.1 for that window. Gilead Sciences appears in 3 tracked Biotech stories published from March 13, 2026 through October 1, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 560 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Gilead Sciences. Shared-story counts are live from our verified record — not editorial picks.
New Limits Reported
States begin implementing restrictive eligibility and waitlists for drug assistance programs.
Fiscal Pressure Mounts
Rising costs of long-acting therapies and expiration of pandemic funding strain state budgets.
Waitlist Peak
National ADAP waitlists reached a record high of over 9,000 individuals following the Great Recession.
Ryan White CARE Act
Federal legislation established to provide a safety net for HIV/AIDS care and treatment.
For biotech and pharma stakeholders, lenacapavir's zero-infection result in a 2,000+ participant trial is a landmark PrEP dataset, but Gilead faces access scrutiny over a $28,000 US price versus $40 generics. WHO recommendation and MSF advocacy signal a licensing and market-access fight ahead.
Source: aljazeera.com · grenadachronicle.com
Several states have begun implementing restrictive eligibility requirements and waitlists for AIDS Drug Assistance Programs (ADAPs), citing budgetary shortfalls and rising medication costs. This shift threatens to reverse years of progress in HIV viral suppression and places significant financial pressure on low-income patients and safety-net providers.
The Florida Legislature has approved a stopgap bill to restore essential funding to the state's AIDS Drug Assistance Program (ADAP), averting a potential crisis in medication access. This legislative action ensures that thousands of low-income residents living with HIV/AIDS will continue to receive life-saving antiretroviral treatments without interruption.
Gilead Sciences is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
